Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma
Introduction Granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma is rare, with a poor prognosis. Advanced urothelial carcinoma is currently treated with immune checkpoint inhibitors, whose efficacy for granulocyte colony‐stimulating factor‐producing upper urinary...
Main Authors: | Hiroki Takeda, Ryuji Matsumoto, Emi Takakuwa, Kanta Hori, Takuya Moriguchi, Shuhei Yamada, Hiroshi Kikuchi, Takahiro Osawa, Takashige Abe, Nobuo Shinohara |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-03-01
|
Series: | IJU Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/iju5.12406 |
Similar Items
-
Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01) -
A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
by: Yousuke Fukiishi, et al.
Published: (2023-03-01) -
The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab
by: Furubayashi N, et al.
Published: (2021-10-01) -
A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
by: Yung-Hao Liu, et al.
Published: (2021-09-01) -
Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
by: Kyotaro Fukuta, et al.
Published: (2021-09-01)